Purpose Ovarian carcinoma in most instances is diagnosed in an advanced stage which cannot be cured by surgical tumor debulking alone. Standard adjuvant chemotherapy usually follows surgical procedures. Yet, few reliable predictive tissue markers exist for the response of ovarian carcinoma to chemotherapy. In this study, we evaluated the predictive value of IL-17-and FOXP3-positive tumor immune cell infiltration (TICI) for response to chemotherapy in ovarian carcinoma. Methods Formalin fixed and paraffin embedded biopsies of mostly high-grade primary serous ovarian carcinomas and their matched recurrences were immunostained with IL-17 and FOXP3 on a tissue microarray. Chemoresistance was defined as tumor recurrence within 6 months of the completion of platinum-based chemotherapy. In 94 and 90 biopsies, conclusive data for IL-17 and FOXP3 were available, respectively. Results IL-17, but not FOXP3-positive TICI, displayed a significantly higher density in biopsies of chemosensitive tumors (p = 0.01). No significant difference in the expression of IL-17 and FOXP3 TICI was observed in all paired primary and recurrent biopsies without respect to chemoresponse (p = 0.77 and p = 0.87, respectively). However, significantly more IL-17-positive recurrences were encountered in the group of patients with chemosensitive tumors (p = 0.008). Conclusions High IL-17-positive TICI is indicative for response to chemotherapy in ovarian carcinoma. Higher frequency of IL-17-positive TICI might persist in recurrent tumor tissues of chemosensitive biopsies, suggesting repetitive platinum-based chemotherapy as an appropriate therapy for patients with IL-17-positive recurrences.
Introduction
Ovarian carcinoma is the fifth most common female cancer with an incidence range of 5-15/100 0 000 in Europe, but the most letal of all female genital carcinomas (Jemal et al. 2010; Ferlay et al. 2010; Bray et al. 2005) . Due to late and unspecific symptoms onset, it is in most instances diagnosed in advanced stages, which cannot be treated by surgery alone. Adjuvant platinum-based chemotherapy usually follows surgical debulking. The vast majority of patients recur with chemoresistant disease.
In order to optimize adjuvant therapy, earlier studies of ovarian cancer analyzed different markers predicting response to platinum-based chemotherapy, but few markers have been identified as useful (He et al. 2008; Sato et al. 1999; Polcher et al. 2010) . It is known that tumor biology influences tumor microenvironment and that tumor behavior is not only affected by the biologic behavior of the neoplastic cells. Evidence points to important influence of tumor-infiltrating immune cells on prognosis and tumor growth (Liotta and Kohn 2001; Stagg 2008; Uppaluri et al. 2008; Oble et al. 2009; Nosho et al. 2010 ). Tumor-infiltrating lymphocytes (TILs) are frequently considered to reflect host immune response to infiltrative neoplasms (Takagi et al. 1989) . They have been shown to infiltrate a variety of tumors from different origins (Galon et al. 2006; Su et al. 2010) . In ovarian cancer, it was shown that FOXP3 positive regulatory T (Treg) cell infiltration is associated with decreased survival (Wolf et al. 2005; Curiel et al. 2004; Polcher et al. 2010 ). Furthermore, it was shown that ovarian cancer-associated CD4-positive Treg cells can be converted into proinflammatory interleukin 17-producing helper T cells (Leveque et al. 2009 ). In addition, it is known that IL-17 can be produced by granulocytes (Li et al. 2010; Lin et al. 2011 ) and other immune cells of the innate immune system (Cua and Tato 2010) . The role of IL-17 tumor immune cell infiltration (TICI) in ovarian carcinoma is still debated. Kryczek et al. (2009) showed that high density of IL-17-positive TICI is associated with improved survival. The predictive value of IL-17-and FOXP3-positive TICI regarding chemotherapy in ovarian cancer therefore merits specific analysis. As the prognostic role of these two immune markers in ovarian carcinoma is well studied, we investigated their predictive value for chemosensitivity in a cohort of primary ovarian carcinomas and their matched recurrences (Stadlmann et al. 2006 (Stadlmann et al. , 2007a (Stadlmann et al. , b, 2008 .
Materials and methods

Patients
Tissues from ovarian serous carcinomas and their recurrences were collected from the Tissue Biobank Basel of the Institutes of Pathology of the University Hospital of Basel and the Cantonal Hospitals of Baden, Liestal and St. Gallen, Switzerland.
Mostly high-grade ovarian carcinomas (5.7 % FIGO stage II, 84.3 % FIGO stage III and 4.3 % FIGO stage IV) were included in this study after typing according to previous publications (Singer et al. 2002 (Singer et al. , 2003 . A tissue microarray (TMA) was constructed which was also used in previous studies (Stadlmann et al. 2006 (Stadlmann et al. , 2007a (Stadlmann et al. , b, 2008 . All patients had recurrences after initial surgery and at least three cycles of platinum-based adjuvant chemotherapy. The collective was clinically divided into chemoresistant or chemosensitive tumors. Resistance was defined as recurrence occurring within 6 months after completion of platinum-based chemotherapy (Jazaeri et al. 2005) . The TMA allowed investigation of tissues from ovarian carcinomas and matched recurrences from the same patients (Stadlmann et al. 2006 (Stadlmann et al. , 2007a (Stadlmann et al. , b, 2008 . The clinical data, including surgical and systemic treatment characteristics, were collected from medical records. All personal data were made anonymous. The present study was performed according to the guidelines of the institutional review boards of the participating institutions in compliance with specific regard to ethical standards and patient confidentiality. The use of this clinically annotated TMA for research was approved by the Regional Ethics Committee previously (Stadlmann et al. 2006 (Stadlmann et al. , 2007a (Stadlmann et al. , b, 2008 .
Tissue microarray construction
Tissue samples fixed in 4 % buffered formalin and embedded in paraffin were used to construct a TMA (Sauter et al. 2003) . Briefly, hematoxylin-eosin stained sections were made from each selected primary block (donor blocks) to define representative tissue regions. Tissue cylinders (0.6 mm in diameter) were then punched from the region of the donor block with the use of a custom-made precision instrument (Beecher Instruments, Silver Spring, MD, USA). Tissue cylinders were transferred to a 25 mm 9 35 mm paraffin block to produce the TMA block used for the study. The resulting TMA block was cut into 3 lm sections, which was transferred to glass slides by use of the Paraffin Sectioning Aid System (Instrumedics, Hackensacks, NJ, USA). Sections from the TMA block were used for the different analyses.
Immunohistochemistry (IHC) and analysis
Standard indirect immunoperoxidase procedures (ABCElite, Vectra Laboratories) were used for immunohistochemistry with the following antibodies: purified polyclonal goat anti-human IL-17 antibody (R&D Systems, Minneapolis, MN, USA), dilution 1:50, polyclonal rabbit IL-17 antibody (sc-7927, H-132, Santa Cruz Biotechnology, Santa Cruz, CA, USA), dilution 1:10 and monoclonal mouse anti-human FOXP3 (clone 236A/E7, Abcam, Cambridge, UK), dilution 1:20. To generate the data used for comparison to chemosensitivity, the purified polyclonal goat anti-human IL-17 antibody (R&D Systems, Minneapolis, MN, USA) was used.
Positively stained TICI in the stroma was counted in each tissue spot, representing approximately one highpower field (4009), intravascular cells were excluded from analysis ( Fig. 1b, d ). Staining was evaluated for specificity and analyzed by two experienced observers (RD and GS). Cutoff was 1 positive cell/punch for both markers. In 94 and 90 biopsies, conclusive data for IL-17 and FOXP3 were available in primary and matched recurrent carcinomas, respectively.
Validation analysis of IL-17 staining
It is known that cells of the innate immune system can produce IL-17 (Cua and Tato 2010; Li et al. 2010; Lin et al. 2011) . Even though that most of the IL-17-positive TICI resembled morphologically lymphocytes granulocytes seemed to stain for IL-17, too. Therefore, we performed a validation staining with two different IL-17 antibodies to assess specificity. The correlation between the two antibodies (AF-317-NA, R&D systems and sc-7927 (H-132), Santa Cruz Biotechnology) was strong and highly significant (r s = 0.78; p \ 0.0001).
The majority of all biopsies (n = 94) were found to be completely negative for IL-17 (n = 55). In the positive biopsies, the number of IL-17 protein expressing cells ranged from 1 to 93.
Statistical analysis section
Cutoff scores used to classify ovarian carcinomas with low or high IL-17 or FOXP3 infiltration were obtained by regression tree analysis, evaluating sensitivity and false positive rate for the discrimination of survivors and nonsurvivors, on all tumor samples (Zlobec et al. 2007 ). Specific scores were set at 1 positive cell/punch for both markers. Wilcoxon and Fisher's exact tests were used to determine the association of IL-17 and FOXP3 infiltration and clinicopathological features for continuous and categorical variables, respectively. Univariate recurrence-free and overall survival analyses were carried out by the Kaplan-Meier method and compared by means of log rank test.
The assumption of proportional hazards was verified for both markers by analyzing the correlation of Schoenfeld residuals and the ranks of individual failure times. Any missing clinicopathological information was assumed to be missing at random. Subsequently, IL-17 and FOXP3 cell infiltration data were entered into multivariate Cox regression analysis and hazard ratios (HR), and 95 % confidence intervals (CI) were used to determine 
Results
Patient characteristics
Patient's median age was 58.5 (34-77) in the chemosensitive and 63 (27-77) in the chemoresistant group, respectively. Recurrence-free and overall survival in the chemoresistant group were significantly shorter than in the chemosensitive group (2.2 ± 0.3 vs. 18.2 ± 2.0 months, p \ 0.0001 and 27 ± 5.3 vs. 49.6 ± 4.0 months, p = 0.0003, respectively). Most patients (94.3 %) had histopathologically high-grade serous papillary carcinomas, and the two groups were comparable according to the FIGO classification (p = 0.47). Furthermore, the analysis of clinicopathological data of the overall cohort by density of IL-17-and FOXP3-positive TICI is summarized in Table 1. IL-17-positive immune cell infiltration in paired primary and recurrent ovarian carcinoma Only 2 out of 14 (14.3 %) chemoresistant primary carcinomas were classified as positive for IL-17
? immune cell infiltration. In the chemosensitive subset, 18 out of 33 (54.5 %) primary carcinomas were positive for IL-17 cell infiltration (Table 2) . Similarly, 2 out of 14 (14.3 %) recurrent chemoresistant carcinomas and 17 out of 33 (51.5 %) recurrent chemosensitive carcinomas were positive for IL-17, respectively. Ten IL-17-negative primary carcinomas samples were positive in their corresponding recurrences. Remarkably, only 2 of them belonged to the chemoresistant patients subset. Nine samples from the chemosensitive patients subset retained their positivity for IL-17 TICI in the corresponding recurrent carcinomas (p = 0.008).
FOXP3-positive immune cell infiltration in paired primary and recurrent ovarian carcinoma
Six out of 13 (46.2 %) primary carcinomas of the chemoresistant and 9 out of 32 (28.1 %) of the chemosensitive subset patients were positive for FOXP3 cell infiltration. The paired recurrences showed 4 out of 13 (30.8 %) chemoresistant carcinomas and 10 out of 32 (31.2 %) chemosensitive carcinomas to be positive for FOXP3. Seven patients that were negative in their primary carcinomas turned to be positive for FOXP3 in their recurrent tumors. Of these 7 patients, 2 were from the chemoresistant subset. Another 7 patients were positive for FOXP3 infiltration in the primary and recurrent carcinoma samples (2 chemoresistant; 5 chemosensitive; Table 2 ).
Distribution of IL-17-and FOXP3-positive TICI according to chemosensitivity
As shown in Fig. 2 , IL-17-positive TICI frequency was significantly higher in the chemosensitive group in all 
Discussion
Adjuvant platinum-based chemotherapy after surgical tumor debulking is a standard procedure. It would be helpful to find markers that help predict response to chemotherapy, in order to include extended chemotherapy regimen and repetitive surgical procedures. Although our previous studies identified potential therapeutical targets in chemoresistant ovarian carcinomas, a reliable predictive marker was not detected (Stadlmann et al. 2006 (Stadlmann et al. , 2007a (Stadlmann et al. , b, 2008 . In this study, we found that IL-17-positive TICI was significantly more frequent in the chemosensitive ovarian carcinoma group. The presence of IL-17 positivity was found to be very similar in primary and recurrent tissues. IL-17-positive TICI was retained in 45 % (9/20) of recurrent carcinomas. Even though that in another 45 % (21/47), the IL-17 status between primary and recurrent tumors switched from positive to negative or vice versa IL-17-positive biopsies were still increased in numbers in the chemosensitive group. Therefore, IL-17 may keep its indicative value for response to platinum-based chemotherapy in recurrent carcinomas. On the other hand, these tumors might simply be less aggressive, either due to host immune or other factors.
FOXP3 is a transcription factor that is mainly expressed in so called regulatory cells with immunosuppressive function (Zou 2006; Tang and Bluestone 2008) . In ovarian cancer, FOXP3 positive Treg cell infiltration has been shown to be associated with significantly worse survival. In this study, FOXP3-positive TICI had no predictive value for response to chemotherapy.
Reviewing the literature, there is an ongoing search for reliable prognostic and predictive markers in ovarian cancer. There is a trend toward individualized treatment based on chemosensitivity assays or gene microarray analyses (Kigawa et al. 2001; Sato et al. 1999) . Tumor immune response is known to play a major role in the control of tumor progression in different types of cancer. Tumor infiltration by CD8-positive T cells has been shown to represent an important prognostic factor in melanoma (Oble et al. 2009 ) and, more recently, in colorectal cancers (Galon et al. 2006; Pages et al. 2005) . Early studies have also suggested a favorable prognostic effect of lymphocyte infiltration in breast cancers (Menard et al. 1997 ). More recently, tumor infiltration by CD3-positive T cells has been proposed to predict responsiveness to neoadjuvant treatment in breast cancer (Denkert et al. 2010) . Furthermore, a predictive effect of breast cancer infiltration by FOXP3-positive cells has also been reported (de Kruijf et al. 2010 ). More aggressive tumors are growing faster and therefore may produce stromal damage possibly related to local hypoxia with necrotic areas (Minervini et al. 2008 ; (Polcher et al. 2010 ). Th17 cells, a subset of CD4 ? T cells characterized by the secretion of high levels of IL-17A, IL-17F and IL-22, play an important role in both the immune response to invading pathogens and autoimmunity as well as transplant rejection (Bettelli et al. 2008) . The specific role of IL-17-positive TICI in ovarian cancer is still debated. There is increasing evidence that IL-17 can be produced by granulocytes (Li et al. 2010; Lin et al. 2011 ) and other immune cells of the innate immune system (Cua and Tato 2010) . In ovarian cancer, it was shown that CD4-positive Treg cells could be converted into proinflammatory interleukin 17-producing helper T cells (Leveque et al. 2009 ). Kryczek et al. (2009) showed that a high density of IL-17-positive TICI is associated with better survival. On the other hand, steady production of TNF-alpha in the tumor microenvironment could increase myeloid cell recruitment in an IL-17-dependent manner and contribute to tumor promotion (Charles et al. 2009 ).
The main limitations of this study are a possible sampling error, but pooling of primary and recurrent samples (n = 94 and n = 90, respectively) confirmed that IL-17, but not FOXP3-positive TICI was significantly more frequent in biopsies of chemosensitive than in biopsies of chemoresistant tumors (Fig. 2) . The potential problem of sufficient sampling is negligible regarding the statistical significance of our results since the low cut off level of one single positive cell/core was applied to all cases and all cores.
In conclusion, IL-17-positive immune cell infiltration could be a promising predictive marker in ovarian carcinoma. It remains to be confirmed in larger series. Furthermore, it would be interesting to investigate if IL-17 might also be of predictive value for second-line (platinumbased) chemotherapy in ovarian carcinoma. Fig. 2 Boxplot distribution of IL-17 and FOXP3 TICI in ovarian carcinomas overall and with respect to chemosensitivity. Boxplot distribution of IL-17 and FOXP3-positive immune cell infiltration in primary (P) and matched recurrent (R) carcinomas in the overall patient cohort and with respect to chemoresponse in all biopsies (CS; CR), primary (P-CS; P-CR) and matched recurrent (R-CS; R-CR) carcinomas; CS chemosensitive, CR chemoresistant
